Hormonal prevention of breast cancer: Proposal for a change in paradigm

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 10, 1999, Pages 1006-1018

  Hesch, R D ^a   Kenemans, P ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTIAZEPAM; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER PREVENTION; FEMALE; GENE MUTATION; HORMONAL REGULATION; HUMAN; MENSTRUAL CYCLE; ONCOGENE; PRIORITY JOURNAL; REVIEW;

BREAST NEOPLASMS; CELL CYCLE; FEMALE; GENES, BRCA1; HORMONE REPLACEMENT THERAPY; HUMANS; MENSTRUAL CYCLE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROGESTERONE; PROGESTINS;

EID: 0032869918     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08106.x     Document Type: Review

References (111)

1. Berg JW, Hutter RV. Breast cancer. Cancer 1995; 75: 257–269.
2. Moller-Jensen O, Estève J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167–1256.
3. Speroff L. Postmenopausal hormone therapy and breast cancer. Obstet Gynecol 1996; 87:44S–54S.
4. Kosary CL et al. editors. SEER Cancer Statistics Review 1973–1992: Tables and Graphs. Bethesda, Maryland, USA: National Cancer Institute, 1996. DHHS Publ No. (NIH) 96–2789.
5. Méndégoz F, Black RJ, Arveux P et al. Cancer incidence and mortality in France in 1975–1995: a study conducted by the European Network of cancer registries in collaboration with the French Cancer registries. Eur J Cancer Prev 1997; 6: 442–466.
6. Newcomb PA, Lantz PM. Recent trends in breast cancer incidence, mortality, and mammography. Breast Cancer Res Treat 1993; 2: 97–106.
7. Ursin G, Bernstein L, Pike MC. Breast cancer. Cancer Sun, 1994; 19–20: 241–264.
8. Beckmann MW, Niedracher D, Schnürch H-G, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med. 1997; 75: 429–439.
9. Kinzler KW, Vogelstein B. Cancer–susceptibility genes. Gatekeepers and caretakers. Nature 1997; 386: 761–763.
10. Kelsey JL, Fischer DB, Holford TR et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981; 67: 327–333.
11. Spicer DV, Pike MC. Breast cancer prevention through modulation of endogenous hormones. Breast Cancer Res Treat 1993; 28: 179–193.
12. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956; 9: 927–934.
13. Feinleib M. Breast cancer and artificial menopause: a cohort study. J Natl Cancer Inst 1968; 41: 315–329.
14. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146–151.
15. Bland KI. Risk factors as an indicator for breast cancer screening in asymptomatic patients. Mafuritas 1987; 9: 135–161.
16. Bodian CA. Biologic markers in breast tissue. Benign breast diseases, carcinoma in situ, and breast cancer risk. Epidemiol Rev 1993; 15: 177–187.
17. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. Am J Epidemiol 1994; 139: 315–329.
18. Osler M. Obesity and cancer: a review of epidemiological studies on the relationship of obesity to cancer of the colon, rectum, prostate, breast, ovaries, andendometrium. Dan Med Bull 1987;34: 267–274.
19. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48: 605–613.
20. Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L. Lifelong menstrual pattern and risk of breast cancer. Oncology 1993; 50: 222–225.
21. Whelan EA, Sandler DP, Root JL, Smith KR, Weinberg CR. Menstrual cycle patterns and risk of breast cancer. Am J Epidemiol 1994; 140: 1081–1090.
22. den Tonkelaar I, De Waard F. Regularity and length of menstrual cycles in women aged 41–46 in relation to breast cancer risk: results from the DOM project. Breast Cancer Res Treat 1996; 38 253–258.
23. Talamini R, Franceschi S, La Vecchia C et al. The role of reproductive and menstrual factors in cancer of the breast before and after menopause. Eur J Cancer 1996; 32A: 303–310.
24. Olsson H, Landin-Olsson M, Gullberg B. Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease. J Natl Cancer Inst 1983; 70:17–20.
25. Yuan J-M, Yu MC, Ross RK et al. Risk factors for breast cancer in Chinese women in Shanghai. Cancer Res 1988; 48:1949–1953.
26. Soini I. Risk factors of breast cancer in Finland. Int J Epidemiol 1977; 6: 365–373.
27. Whelan E, Sander DP, Root JL et al. Menstrual cycle patterns and risk of breast cancer. Am J Epidemiol 1994; 140: 1081–1090.
28. Garland M, Hunter DJ, Colditz GA et al. Menstrual cycle characteristics and history of ovulatory infertility in relation to breast cancer risk in a large cohort of US women. Am J Epidemiol 1998; 147: 636–643.
29. Cooper GS, Sander DP, Whelan EA, Smith KR. Association of physical and behavioural characteristics with menstrual cycle patterns in women age 29–31 years. Epidemiol 1996; 7: 624–628.
30. Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the ‘resting’ human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982; 46: 376–382.
31. Longacre TA, Bartow SA. A Correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382–393.
32. Madjar H, Vetter M, Prompeler HJ, Wieacker P, Schillinger H. Untersuchungen zur normalen Vaskularisation der weiblichen Brust. UltraschallMed 1992; 13: 171–177.
33. Plu-Bureau G, Thalabard JC, Sitruk-Ware R, Asselain B, MauvaisJarvis P. Cyclical mastalgia as a marker of breast cancer susceptibility: results of a case–control study among French women. Br J Cancer 1992; 65: 945–949.
34. Goodwin PJ, De Boer G, Clark RM et al. Cyclical mastopathy and premenopausal breast cancer risk results of a case control study. Breast Cancer Res Treat 1994; 33: 63–73.
35. Korenman SG. Oestrogen window hypothesis of the aetiology of breast cancer. Lancet 1980; 1: 700–701.
36. Henderson EB, Ross RK, Judd H, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk Cancer 1985; 56: 1206–1208.
37. Waard de F, Trichopoulos D. A unifying concept of the aetiology of breast cancer. Int J Cancer 1988; 41: 666–669.
38. den Tonkelaar I. Fat distribution, menstrual history and breast cancer risk. MD Thesis, Universiteit Utrecht, 1995.
39. Hiushesky W, Peace D, Wood P. Fertility cycle modulation of breast cancer growth. Breast Cancer Res Treat 1996; 41: 272.
40. Miki Y, Swensen J, Shattuck-Edens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
41. Wooster R, Neuhausen SI, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12–q13. Science 1994; 265: 2088–2090.
42. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. Molecular genetic evidence of the Occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996; 77: 1836–1843.
43. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278: 1242–1250.
44. Frank TS, Manley SA, Olopade OI et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16: 2417–2425.
45. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. P53 mutation partially rescues developmental arrest in Brcal and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. Nat Med 1997; 3:721–722.
46. Hakem R, de la Pompa, JL, Elia A, Potter J, Mak TW. Partial rescue of Brcal (5–6) early embryonic lethality by P53 or p21 null mutation. Nut Genet 1997; 16: 298–302.
47. Lim DS, Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 1996; 16: 7133–7143.
48. D'Souza D, Thomas IM, Das BC. Variation in spontaneous chromosomal damage as a function of biologic rhythms in women. Hum Genet 1988; 79: 83–85.
49. Sharan SK, Morimatsu M, Albrecht U et al. Embryonic lethality and radiation hypersensitivity mediated by rad51 in mice lacking Brca2. Nature 1997; 386 804–810.
50. Ladona MG, Abildúa RE, Ladero JM et al. CYP2 D6 genotypes in Spanish women with breast cancer. Cancer Lett 1996; 99: 23–28.
51. Sabourin JC, Martin A, Baruch J, TNC JB, Gompel A, Poitout P. bcl-2 expression in normal breast tissue during the menstrual cycle. Int J Cancer 1994; 59: 1–6.
52. Silvestrini R, Veneroni S, Daidone MG et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph nodenegative breast cancer patients. J Natl Cancer lnst 1994; 86: 499–504.
53. Hunter DJ, Hankison SE, Laden F et al. Plasma organochlorine levels and the risk of breast cancer. N Engl J Med 1997; 337: 1253–1258.
54. vom Saal FS, Timms BG, Montano MM et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997; 94: 2056–2051.
55. Bigsby RM, Caperell-Grant A, Madhukar BV. Xenobiotics released from fat during fasting produce estrogenic effects in ovariectomized mice. Cancer Res 1997; 57: 865–869.
56. Marks JR, Huper G, Vaughn JP et al. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997; 14: 115–121.
57. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med 1991; 151:67–72.
58. Kenemans P, Scheele F. Hormone replacement therapy in patients at risk of developing breast cancer: the use of a combined risk model. Gynecol Endocrinol 1997; 11 (Suppl 1): 17–22.
59. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047–1059.
60. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996; 88:365–371.
61. Sellers TA, Mink PJ, Cerhan JR et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997; 127: 973–980.
62. Couch FJ, DeShano ML, Blackwood A et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336: 1409–1415.
63. Saad Z, Bramwell VHC, Wilson SM et al. Expression of genes that contribute to proliferative and metastatic ability in breast cancer resected during various menstrual phases. Lancet 1998; 351: 1170–1173.
64. Hiyami E, Gollahon L, Kataoka T et al. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88: 116–122.
65. Sugino T, Yoshida K, Bolodeoku J et al. Telomerase activity in human breast cancer and benign breast lesions: diagnostic applications in clinical specimens, including fine needle aspirates. Int J Cancer 1996; 69: 301–306.
66. Hesch RD. Teil A Grundlagen einleitung. In: Endokrinologie. München: Urban und Schwarzenberg, 1989: 1–49.
67. Knippers R. Molekulare Genetik. Stuttgart: Thieme Verlag 1995: 235–259.
68. Morgan DO. Principles of cdk regulation. Nature 1995; 374 131–134.
69. 1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin–dependent kinase inhibitor association with cyclin E–Cdk2. J Biol Chem 1997; 272: 10882–10894.
70. Theriault RL. Hormone replacement therapy and breast cancer: an overview. Br J Obstet Gynaecol 1996; 103: 87–91.
71. Longman SM, Buehring GC. Oral contraceptives and breast cancer. Cancer 1987; 59: 281–287.
72. Vogel PM, Geogiade NG, Fetter BE, Vogel FS, McCarty KS. The correlation of histologic changes in the human breast with the menstrual cycle. Am J Pathol 1981; 104: 23–34.
73. Sutherland RL, Watts CKW, Musgrove EA. Cell cycle control by steroid hormones in breast cancer: implications for endocrine resistance. Endocr Rel Cancer 1995; 2: 81–96.
74. Anderson TI, Battersby S, King RJB. McPherson K, Going JJ. Oral contraceptive use influences breast cell proliferation. Hum Path 1989; 20: 1139–1141.
75. Potten CS, Watson RJ, Williams GT et al. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163–170.
76. Chang KJ, Lee TTY, Linares-Cruz G, Fournier S, De Lignieres B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. Fed Steril 1995; 63: 785–791.
77. Barrat J, De Lignieres B, Marpeau L et al. Effet in vivo de l' administration locale de progesterone sur l'activé mitotique des galactophores humains. J Gynecol Obstet Biol Reprod 1990; 19: 269–274.
78. Maudelonde T, Lavaud P, Salazar G, Rochefort H. Progestin treatment depresses oestrogen receptor but no cathepsin D levels in needle aspirates of benign breast disease. Breast Cancer Res Treat 1991; 19: 95–102.
79. Söderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 1997; 176: 123–128.
80. von Schoultz B, Söderqvist G, Cline M. von Schoultz E, Skoog L. Hormonal regulation of the normal breast. Maturitas 1996; 23 (Suppl): S23–S25.
81. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990; 11: 266–301.
82. Mullick A, Katzenellenbogen BS. Progesterone receptor synthesis and degradation in MCF–7 human breast cancer cells as studied by dense amino acid incorporation. Evidence for a non–hormone binding receptor precursor. J Biol Chem 1986; 261: 13236–13243.
83. Pollow K, Boquoi E. Baumann J, Schmitt-Collwitzer M, Pollow B. Comparison of the in-vitro conversion of estradiol 17–(beta) to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977; 6: 333–348.
84. Kipl. Mol Endocrinol 1997; 11: 1593–1607.
85. Söderqvist G. Sex steroid effects on normal breast tissue. MD Thesis: Karolinska University Hospital, Stockholm, 1996.
86. Söderqvist G, Olsson H, Wilking N, von Schoultz B, Carlström K. Metabolism of estrone sulfate by normal breast tissue: influence of menopausal status and oral contraceptives. J Steroid Biochem Mol Biol 1994; 48: 221–224.
87. Malet C, Gompel A, Yaneva A et al. Estradiol and progesterone receptors in cultured normal human breast epithelial cells and fibroblasts: immunocytochemical studies. Clin Endocrinol Metab 1991; 73: 8–17.
88. Horwitz KB, Koseki Y, McGuire WL. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen. Endocrinol 1978; 103: 1742–1751.
89. Vering A, Vockel A, Stegmuller M, Bender HG. Immuno–biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy. J Cancer Res Clin Oncol 1993; 119 415–420.
90. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996; 174: 93–100.
91. Paul I, Skegg DC, Spears GF. Depot medroxyprogesterone (Depo–Provera) and risk of breast cancer. BMJ 1989; 299.59–762.
92. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot medroxyprogesterone acetate. A multinational study. Lancet 1991; 388: 833–838.
93. Mol JA, Van Garderen E, Rutteman GR, Rijnberk A. New insights in the molecular mechanism of progestin–induced proliferation of mammary epithelium: induction of the local biosynthesis of growth hormone (GH) in the mammary glands of dogs, cats and humans. J Steroid Biochem Mol Biol 1996; 57: 67–71.
94. Campagnoli C, Biglia N, Cantamessa C, Di Sario MM, Lesca L. Effect of progestins on IGF–1 serum level in estrogen–treated postmenopausal women. Zentralbl Gynakol 1997; 119: 7–11.
95. Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Contraception 1989; 40: 1–38.
96. Kenemans P, Scheele F, Burger CW. Hormone replacement therapy and breast cancer morbidity, mortality and recurrence. Eur J Obsret Gynecol Reprod Med 1997; 71: 199–203.
97. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713–1727.
98. Sitruk-Ware R. Hormones et sein. Rev Prat Gynécol Obstet 1997; 14 15–18.
99. Ewertz M. Influence of non–contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988; 42: 832–838.
100. Bergkvist L, Adami H-O, Persson I et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen–progestogen replacement therapy. Am J Epidemiol 1989; 130: 221–228.
101. Stanford JL, Weiss NS, Voigt LF et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle–aged women. JAMA 1995; 274: 137–142.
102. La Vecchia C, Negri E, Franceschi S et al. Hormone replacement treatment and breast cancer risk a cooperative Italian study. Br J Cancer 1995; 72: 244–248.
103. Ettinger B, Quesenberry C, Schroeder DA, Friedman G. Longterm postmenopausal estrogen therapy may be associated with increased risk of breast cancer: a cohort study. Menopause 1997; 4: 125–129.
104. Willis DB, Calle EE, Miracle-McMahill HL, Heath, CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 449–457.
105. McKeon VA. The breast cancer prevention trial: evaluating tamoxifen's efficacy in preventing breast cancer. J Obstet Gynecol Neonatal Nurs 1997; 26: 79–90.
106. Vanchieri C. Breast cancer prevention study initiated in Italy. J Natl Cancer Inst 1992; 84: 1555–1556.
107. Josefson D. Breast cancer trial stopped early. BMJ 1998; 316: 1185.
108. Powles T, Eeles R, Ashley S et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98–101.
109. Veronesi U, Maisonneuve P, Costa A et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998; 352: 93–97.
110. Prichard KI. Is tamoxifen effective in prevention of breast cancer Lancet 1998; 352: 80–81.
111. Eden JA, Bush, TNS and Wren BG. A case–control study of combined continuous estrogen–progestin replacement therapy among women with a personal history of breast cancer. Menopause: J Am Menopause SOC 1995; 2: 67–72.